Led by Distinguished Professor Margaret Brimble, the research group comprised of highly qualified and experienced researchers located at The University of Auckland.


With specialist interests in asymmetric synthesis, heterocyclic chemistry and organocatalysis, the research group use their extensive expertise to synthesise complex bioactive natural products. The synthesis of complex glycopeptides, lipopeptides, labelled peptides, peptidomimetics and long peptides is readily undertaken within the research programme, often in collaboration with biotechnology companies and institutes.

The group have a proven track record in the field of peptide chemistry, with peptide-based drug candidates now in clinical trials. Trofinetide (NNZ-2566) is currently in Phase 2 clinical trials for traumatic brain injury, concussion, fragile X syndrome and Rett syndrome (see Neuren Pharmaceuticals). The group also involved in the synthesis of melanoma vaccines under cGMP which is currently in Phase 1 trial.

The research is facilitated by rigorous structure determination using nuclear magnetic resonance, mass spectrometry and X-ray crystallography. Our peptide laboratory is also equipped with several fully automated solid phase synthesisers, semi-preparative HPLC and LCMS.